Elimusertib

N/A

Report date: 2023/05/05 18:02:47
NME

Base Information

Drug NameElimusertib
Drug Alias NameBAY-1895344
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine-protein kinase ATR inhibitors
TargetsSerine-protein kinase ATR
Therapy Area/IndicationsBone metastasesSolid tumoursParanasal Sinus Diseases +[42] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteBayer AGBayer Healthcare Company Ltd
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsSolid tumoursParanasal Sinus DiseasesUrologic Neoplasms +[40] 
Inactive IndicationsBone metastasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A